What We Have Gained from Ibogaine: α3β4 Nicotinic Acetylcholine Receptor Inhibitors as Treatments for Substance Use Disorders
Researchers reviewing ibogaine and its chemical relatives say these drugs point to a new way to treat substance use disorders by blocking a brain receptor called α3β4 nicotinic acetylcholine receptor (nAChR). Animal studies found ibogaine and some derivatives reduced self-use of drugs like morphine, cocaine, alcohol, and nicotine. But ibogaine…